Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy: a Randomized, Open-label, Phase II Trial (CR1STAL-Adaptive)

NCT06951646 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.

NCT NCT06951646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06951646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy: a Randomized, Open-label, Phase II Trial (CR1STAL-Adaptive)
Lead sponsor
Second Xiangya Hospital of Central South University
Phase
Phase 2
Overall status
Recruiting
Start date
March 10, 2026
Completion date
June 1, 2030
Enrollment
70 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

immune checkpoint inhibitors (icis), non small cell lung cancer